ライフサイエンスコーパス: transgenic mouse

1 ssed for function in cultured cells and in a transgenic mouse.

2 we used an autoimmune-prone T-cell receptor transgenic mouse (2D2) and a mouse-adapted human influen

3 Using a NOX2 transgenic mouse and a pig model of rapid atrial pacing,

4 h beta-cell development or maintenance using transgenic mouse approaches.

5 We developed a transgenic mouse, Arl13b-mCherry-GECO1.2, expressing a r

6 idated a subset of these in cell culture and transgenic mouse assays.

7 man basophils and the human FcepsilonRIalpha transgenic mouse bone marrow-derived mast cells via driv

8 onal differences between Tau aggregates from transgenic mouse brain and in vitro assembled recombinan

9 tions and ex vivo autoradiography studies in transgenic mouse brain sections show cortical Abeta bind

10 ring protocols with the FACT protocol, using transgenic mouse brains with fluorochrome expression in

11 , tau expression was elevated in TDP-43M337V transgenic mouse brains.

12 n HD mouse- and patient-derived cells and HD transgenic mouse brains.

13 stases in the mammary tumor virus (MMTV)-Neu transgenic mouse breast cancer model.

14 study, we generated a Notch gain-of-function transgenic mouse by conditionally overexpressing the Not

15 wnstream components in early symptomatic R9C transgenic mouse cardiomyocytes compared with wild type

16 Using brief (3 h) exposure of TCR-transgenic mouse CD8 T cells in vitro to varying densiti

17 Functional studies in transgenic mouse cells show that XACT influences XIST ac

18 The Emu-TCL1 transgenic mouse develops a form of leukemia that is sim

19 algorithms using single cells from Etv2-EYFP transgenic mouse embryos and reveal specific molecular p

20 r second heart field (pSHF) of Tbx5 and Osr1 transgenic mouse embryos, a time-course gene expression

21 To validate these studies in vivo, a transgenic mouse encoding EGFP under the control of this

22 imately 4000 copies of the ERV-9 LTRs and in transgenic mouse erythroblasts carrying a single copy of

23 sangial cells and in an inducible human Nox5 transgenic mouse exposed to streptozotocin-induced diabe

24 ic cells and their progenies by generating a transgenic mouse expressing a chimaeric protein in which

25 this article, we report the development of a transgenic mouse expressing human CD22 (hCD22) in B cell

26 vivo cerebral ischemia model, we developed a transgenic mouse expressing human CD39 (hCD39).

27 Here we use a transgenic mouse-expressing POP2 controlled by its endog

28 sed in postconception day E18 human beta-YAC transgenic mouse fetal liver.

29 In CR2-GFP transgenic mouse, GFP expression was found prominent in

30 filament protein into adulthood in the ssTnI-transgenic mouse heart induced downregulation of the gen

31 ion of PR3 in vivo, we generated a human PR3 transgenic mouse (hPR3Tg).

32 radio and TV were abuzz with the story of a transgenic mouse in London called Randy.

33 Furthermore, using a triple transgenic mouse in which all of the Cav1.2(KO) OPCs wer

34 brain slices or in vivo Here, we describe a transgenic mouse in which expression of Optopatch constr

35 We used a transgenic mouse in which Mef2a, -c, and -d were inducib

36 Using a transgenic mouse in which the promoter for the 5-HT3a su

37 Therefore the crym-GFP transgenic mouse is a useful tool for studies of CST ana

38 d Ca(2+) fluxes were all markedly reduced in transgenic mouse islets, whereas glucose-induced oxygen

39 and Tnf expression in human IAPP-expressing transgenic mouse islets.

40 4 in vitro and in the podocyte-specific NOX4 transgenic mouse led to reduced FH levels.

41 Mice of an IL-25 transgenic mouse line (iIL-25Tg mice), which constitutiv

42 duced CNS alphaS pathology in another alphaS transgenic mouse line (M20), albeit less robustly in the

43 eding the hypomorphic mutant with a rescuing transgenic mouse line bearing a 662-kb Gata3 yeast artif

44 The mAPP(-/-) mice crossed to an APP/PS1 transgenic mouse line demonstrated reduced microgliosis

45 For this purpose, we first validated a transgenic mouse line expressing cre recombinase in hist

46 is the first time overexpression of AS in a transgenic mouse line has shown an ability to induce HP.

47 A transgenic mouse line in which the CD68 promoter ensures

48 Here, we used a transgenic mouse line in which vasoactive intestinal pol

49 Furthermore, a transgenic mouse line specifically labeling SL cells sho

50 ral sclerosis pathogenesis by crossing a new transgenic mouse line that overexpresses OXR1 in neurons

51 We report the development of a transgenic mouse line where Cre-recombinase-induced expr

52 Here, using a transgenic mouse line with destabilized GFP, we identifi

53 advantage of the cell-type specificity of a transgenic mouse line, the GN220-Ntsr1 Cre line, to mani

54 cells, and macrophages isolated from a Cas9 transgenic mouse line.

55 ression in unintentionally targeted cells in transgenic mouse lines can confound the interpretation o

56 tersectional strategies to generate multiple transgenic mouse lines expressing high levels of novel g

57 To address this hypothesis, we generated transgenic mouse lines harboring a Gata1 bacterial artif

58 g ERK1/2 activity in myelinating cells using transgenic mouse lines in which ERK1/2 activation was up

59 ere T cells derived from two independent TCR transgenic mouse lines recognize the same melanoma antig

60 munoblotting studies of selectively bred and transgenic mouse lines revealed a positive correlation b

61 f EYFP(Vglut2) , EYFP(Vgat) , and GFP(Gad67) transgenic mouse lines revealed that, like GnRH neurons,

62 of the GARPs, we have characterized several transgenic mouse lines selectively restoring GARPs on a

63 We generated stable transgenic mouse lines that express CreER(T2) and GFP fr

64 al expression system, here we generated Plk1 transgenic mouse lines to examine the role of Plk1 in tu

65 Recent studies using transgenic mouse lines to target specific BF cell types

66 Recent studies using transgenic mouse lines to target specific cell types in

67 is review includes a list of the various Cre transgenic mouse lines used to achieve tooth root format

68 e pathogenesis of these diseases, we created transgenic mouse lines using human CFH bacterial artific

69 ndrogenesis, myelination, and remyelination, transgenic mouse lines were generated in which a modifie

70 ead occlusion model of glaucoma to different transgenic mouse lines, each expressing green fluorescen

71 Furthermore, in a panel of transgenic mouse lines, we demonstrate that overexpressi

72 ransgenesis or knock-in has generated useful transgenic mouse lines.

73 ted tissue-specific cell cycle indicator BAC transgenic mouse lines.

74 of programmed death-ligand 1 (PD-L1) in Her2 transgenic mouse mammary tumors, with high expression li

75 Using a Ret transgenic mouse melanoma model, we found an accumulatio

76 hy, the retina of the P301S mutant human tau transgenic mouse, mild tau pathology results in function

77 ire breadth to a non-self-antigen, a TCRbeta transgenic mouse model (EF4.1) expressing a limited, yet

78 Here, we developed a transgenic mouse model (NRG1-IV/NSE-tTA) in which human

79 ified a beneficial taxonomic repertoire in a transgenic mouse model (RIP140mvarphiKD) which resists t

80 riven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Mal

81 We generated a transgenic mouse model (TNF-alpha(glo)) that could be us

82 riggers, could prevent disease symptoms in a transgenic mouse model and a knockin mouse model of the

83 urther generated a corresponding betaH1-eGFP transgenic mouse model and demonstrated the presence of

84 t manner, and is strongly activated in 5XFAD transgenic mouse model and human AD brains.

85 interstitial fluid (ISF) and CSF from an AD transgenic mouse model and postmortem ventricular and an

86 This work describes the first double transgenic mouse model bearing both human FcRn and HSA g

87 first report of a newly generated humanized transgenic mouse model engineered to express human NRG1-

88 Here, we present a novel transgenic mouse model expressing a hepatocyte-specific

89 In this study, we present a transgenic mouse model expressing a photoactivated adeny

90 This transgenic mouse model expressing an ERalpha folding-bio

91 Boosting a transgenic mouse model expressing germline VRC01 heavy c

92 c alleviated S. pyogenes-induced sepsis in a transgenic mouse model expressing human FH (S. pyogenes

93 Here we show in a transgenic mouse model expressing mutant human tau predo

94 er mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOG

95 We generated a transgenic mouse model expressing the E7 oncoprotein of

96 he advantages and limitations of the HLA-DR4 transgenic mouse model for evaluating human C. trachomat

97 id leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia.

98 exanucleotide repeat expansion in ALS/FTD, a transgenic mouse model has remained elusive.

99 Using a transgenic mouse model in which FlnA is selectively depl

100 severative behaviors, we characterized a new transgenic mouse model in which inducible ablation of SC

101 cted CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted

102 V-induced skin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter

103 We have developed a new transgenic mouse model in which we can induce expression

104 Here, we describe a transgenic mouse model in which we expressed a mitochond

105 This hAS transgenic mouse model is therefore an ideal animal mode

106 fic dominant-negative (DN) TCF7L2 (TCF7L2DN) transgenic mouse model LTCFDN.

107 uppress the Alzheimer's-like phenotypes in a transgenic mouse model of Abeta deposition.

108 to investigate brain copper trafficking in a transgenic mouse model of AD by PET imaging with (64)Cu,

109 that reducing endogenous alpha-syn in an APP transgenic mouse model of AD prevented the degeneration

110 In a transgenic mouse model of AD, aducanumab is shown to ent

111 In an APP transgenic mouse model of AD-like amyloid pathology we f

112 which demonstrated oral activity in a triple-transgenic mouse model of AD.

113 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model of AD.

114 we confirm these results in vivo by using a transgenic mouse model of AD.

115 genous alpha-synuclein (alpha-syn) in an APP transgenic mouse model of Alzheimer's disease (AD) preve

116 S)-induced microglia activation in vivo in a transgenic mouse model of Alzheimer's disease (APP/PS1)

117 subsequent fluorescent amyloid staining in a transgenic mouse model of Alzheimer's disease (tgSwe).

118 el of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer's disease.

119 d in affected neuronal tissues from a TDP-43 transgenic mouse model of amyotrophic lateral sclerosis

120 In a transgenic mouse model of androgen-responsive prostate c

121 are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by

122 D8+ T cells are implicated as effectors in a transgenic mouse model of autoimmune GFAP meningoencepha

123 In an S100A7 transgenic mouse model of breast cancer (mS100a7a15 mice

124 of CaSR-PTHrP interactions in the MMTV-PymT transgenic mouse model of breast cancer and in human bre

125 In the MMTV-PyMT transgenic mouse model of breast cancer and in oral squa

126 results in suppression of tumour growth in a transgenic mouse model of breast cancer.

127 W)-MRI in the polyoma virus middle T antigen transgenic mouse model of breast cancer.

128 igated the impact of gammadelta T cells in a transgenic mouse model of carcinogenesis induced by HPV1

129 METHODS AND Using a transgenic mouse model of cardiac lipotoxicity overexpre

130 We used a transgenic mouse model of chronic lung disease induced b

131 vivo relevance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interfere

132 In this study we have used a transgenic mouse model of dementia (rTg4510 mice), which

133 logical approaches, we have shown that, in a transgenic mouse model of dementia, the functional prope

134 GMP signaling.SIGNIFICANCE STATEMENT In DYT1 transgenic mouse model of dystonia, PDE10A, a key enzyme

135 nt stem cells into the anterior chamber of a transgenic mouse model of glaucoma.

136 and improves phenotype and survival in R6/2 transgenic mouse model of HD.

137 ilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle

138 In the K14-HPV16 transgenic mouse model of HPV-driven neoplasms, direct c

139 Using an established transgenic mouse model of HPV16 E7-induced HNSCC, we dem

140 duced in striatal output neurons of the R6/2 transgenic mouse model of Huntington's disease, at an ag

141 dependent microvascular disease is seen in a transgenic mouse model of IFN toxicity.

142 Using a human islet amyloid polypeptide transgenic mouse model of islet amyloidosis, we show ARC

143 In this study, we describe a transgenic mouse model of KRAS-driven lung adenocarcinom

144 In a syngeneic HLA-A2-transgenic mouse model of large established tumors, we f

145 xoguanine DNA glycosylase (OGG1) in the PyMT transgenic mouse model of mammary tumorigenesis.

146 ymal transition and metastasis, an MMTV-PyMT transgenic mouse model of mammary tumour progression and

147 teolipid protein alpha-syn (PLP-SYN) mice, a transgenic mouse model of MSA.

148 patients and reduced IGF-1 brain levels in a transgenic mouse model of multiple system atrophy.

149 Using a "humanized" transgenic mouse model of nasal colonization, we took a

150 (iii) Immunization of an HLA-A*02:01 transgenic mouse model of ocular herpes with "ASYMP" CD8

151 Using a transgenic mouse model of Parkinson's disease (PD) that

152 our results show in an aggressively growing transgenic mouse model of PDAC that the coordinated acti

153 We previously generated a transgenic mouse model of PPFP thyroid carcinoma and sho

154 nic adenocarcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer.

155 We used a transgenic mouse model of pulmonary arterial hypertensio

156 In a transgenic mouse model of resectable PDAC, we investigat

157 We validated this method in a transgenic mouse model of selective podocyte depletion,

158 emporal structure of SWRs was disrupted in a transgenic mouse model of tauopathy (one of the major ha

159 s, neuroinflammation, neurodegeneration in a transgenic mouse model of tauopathy.

160 Here we introduce the first transgenic mouse model of uveal melanoma, which develops

161 To test this, we used a previously described transgenic mouse model of wound-induced skin tumorigenes

162 in DIV7 cortical cultures of either from E18 transgenic mouse model or from rat E18 embryos that were

163 Aha1 overexpression in the rTg4510 tau transgenic mouse model promoted insoluble and oligomeric

164 Here we report that, in a transgenic mouse model simulating the duplication condit

165 We developed a transgenic mouse model that allows for lung-specific exp

166 We developed a transgenic mouse model that constitutively expresses a f

167 Previous studies described a TDP-43(A315T) transgenic mouse model that develops progressive motor d

168 Here, we have generated a double-transgenic mouse model that expresses human CD1b and CD1

169 Our transgenic mouse model that expresses LacZ reporter unde

170 We created a transgenic mouse model that expresses the pH-dependent f

171 Using a transgenic mouse model that inducibly expresses Dkk1 in

172 In this issue of the JCI, Pham et al. use a transgenic mouse model to demonstrate that STAT5BN642H i

173 gionally restricted and temporally regulated transgenic mouse model to investigate the behavioral, mo

174 We developed a triple-transgenic mouse model to map the fate of NG2(+)CD146(+)

175 To address this, we used a transgenic mouse model where Lamin B1 overexpression is

176 ediated skin cancer by interbreeding an HPV8 transgenic mouse model with a conditional disruption of

177 of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3

178 ere, we report the generation of a claudin-1 transgenic mouse model with doxycycline-inducible transg

179 s phenomenon, we have developed an inducible transgenic mouse model with expression of the most commo

180 p52 expression in vivo, we generated a novel transgenic mouse model with inducible expression of p52

181 ional effects of TMPRSS2:ERG expression in a transgenic mouse model with those of ERG knockdown in a

182 We showed that in a transgenic mouse model, activation of the UPR in early d

183 s decreased in the brains of AD patients and transgenic mouse model, as well as Abeta-treated cells.

184 In a somatic transgenic mouse model, depletion of Bcl6 inhibits the p

185 ue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation o

186 Using the TRAMP transgenic mouse model, glipizide, a widely used drug fo

187 ation and improves survival in a calcineurin transgenic mouse model, indicating that COUP-TFII may se

188 e therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, with abundant vascular

189 The authors generated a double-transgenic mouse model, tTAxalphaMHCR403Q, in which expr

190 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK

191 Using our transgenic mouse model, we found that tetherin expressio

192 Here, using a tissue-specific miRNA transgenic mouse model, we show that interaction between

193 Herein, we use a novel transgenic mouse model, where doxycycline-induced overex

194 ectrophysiological recordings in the rTg4510 transgenic mouse model, which overexpresses a mutant for

195 with cognitive improvements in an AD APP/PS1 transgenic mouse model.

196 ase (SCD) in a NRF2 knockout (SCD/NRF2(-/-)) transgenic mouse model.

197 apoptosis mediated by the p53 pathway in our transgenic mouse model.

198 cells, using a unique T cell receptor (TCR) transgenic mouse model.

199 impaired decidualization in both women and a transgenic mouse model.

200 progression of retinal pathology in a PD/DLB transgenic mouse model.

201 was further demonstrated in vivo using a CLL transgenic mouse model.

202 different EAE models, including the 2D2 TCR-transgenic mouse model.

203 and elicit functional improvement in an aged transgenic mouse model.

204 ing breast cancer progression in a MMTV-PyMT transgenic mouse model.

205 etworks and inhibited tumor progression in a transgenic mouse model.

206 ed Jagged1 using osteoblast-specific Jagged1 transgenic mouse model.

207 stemic anaphylaxis in human FcepsilonRIalpha transgenic mouse model.

208 tissue; CC cell xenografts; a p53-deficient transgenic mouse model; and a non-transgenic, chemically

209 Using various inducible and site-specific transgenic mouse models and pharmacological validation e

210 Transgenic mouse models expressing mutant superoxide dis

211 Using transgenic mouse models for cell-specific HIF expression

212 t composition in the skin, we have generated transgenic mouse models for tamoxifen-inducible de novo

213 ) and previously undescribed (G2-Gata4(Cre)) transgenic mouse models for the study of coronary vascul

214 n the majority of Rett Syndrome (RTT) cases, transgenic mouse models have played a critical role in o

215 ine phosphatases Shp1 and Shp2, knockout and transgenic mouse models have revealed distinct phenotype

216 We studied autoresuscitation in two transgenic mouse models in which exocytic neurotransmitt

217 injury pharmacologically and genetically in transgenic mouse models in which microglia and systemic

218 Lesions of the LC in amyloid-based transgenic mouse models of AD exacerbate Abeta pathology

219 ortem brain tissue samples from AD patients, transgenic mouse models of AD, and neuronal cells were u

220 ulates amyloidosis and memory impairments in transgenic mouse models of Alzheimer's disease.

221 s amyloid aggregation in cells, worms and in transgenic mouse models of Alzheimer's disease.

222 29 would attenuate pulmonary hypertension in transgenic mouse models of Bmpr2 mutation.

223 derived tumor xenograft (PDX) and MYC-driven transgenic mouse models of breast cancer by inhibiting t

224 a result of tumor formation in two different transgenic mouse models of cancer (RIP1-Tag2 model of in

225 Using transgenic mouse models of cancer, we found that express

226 Here we show that in transgenic mouse models of early AD, direct optogenetic

227 Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential no

228 breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer.

229 emonstrate a significant analgesic effect in transgenic mouse models of SCD and cancer as well as com

230 ion of SMN protein in human cells and in two transgenic mouse models of SMA.

231 s mutant SOD1 expression is recapitulated in transgenic mouse models of the disease.

232 To address this gap, we developed two transgenic mouse models on the C57BL/6 background by ove

233 Here, we use transgenic mouse models producing CAA mutants (Tg-SwDI)

234 in LTP/LTD magnitude seen across ages in AD transgenic mouse models reflect the inability to undergo

235 Evidence from transgenic mouse models suggests mutant forms of FUS exe

236 Here, we provide evidence from transgenic mouse models that Crebbp deletion results in

237 Here, we used the Vav1 promoter to generate transgenic mouse models that expressed either human STAT

238 Despite the extensive use of transgenic mouse models to investigate the propagation o

239 METHODS AND To address the question, 2 transgenic mouse models were generated: a phospho-mimeti

240 er-induced choroidal neovascularization, and transgenic mouse models with deficient or spontaneous re

241 Transgenic mouse models with human monogenic-migraine-sy

242 Using transgenic mouse models, cell line-based functional stud

243 st time Pcdh10 up-regulation in tissues from transgenic mouse models, cultured Schwann cells, and hum

244 ow for the first time that, unlike other tau transgenic mouse models, minimal expression of a human d

245 Using transgenic mouse models, these results demonstrate that

246 Using transgenic mouse models, we demonstrate that lymphatic e

247 Using transgenic mouse models, we show that B-cell-specific co

248 tau protein aggregation both in vitro and in transgenic mouse models.

249 ed this hypothesis, using highly replicative transgenic mouse models.

250 using tetracycline- and tamoxifen-inducible transgenic mouse models.

251 of Interleukin (IL)-10 in the brains of APP transgenic mouse models.

252 ain and in Abeta precursor protein (AbetaPP) transgenic mouse models.

253 ogenous IAPP in islet cultures obtained from transgenic mouse or healthy human pancreas.

254 We generated a transgenic mouse overexpressing exogenous FUS without a

255 This study used a novel transgenic mouse paradigm to ablate proliferating NG2(+)

256 the E-box element was confirmed in the hGH1 transgenic mouse pituitary in situ Occupancy was reduced

257 rom neural stem cells that were derived from transgenic mouse pre-labeled with enhanced green fluores

258 uding B16 melanoma, Lewis lung carcinoma and transgenic mouse prostate cancer-C2 cancer cells.

259 eam effectors Grp78/BiP and eIF2alpha in ERG transgenic mouse prostate glands indicate the presence o

260 Epithelial cells derived from ERG transgenic mouse prostates have increased prostasphere f

261 characterize these changes further, we used transgenic mouse reagents to delineate neuronal circuitr

262 Transgenic mouse reporter assays revealed that the in vi

263 NF-kappaB signalling-deficient IkappaBDeltaN transgenic mouse rescues NKT cell development and differ

264 reduced inhibition of cGMP production in the transgenic mouse retinas at the free calcium concentrati

265 A transcript was barely changed in the fat-1 transgenic mouse skin.

266 del we used wild-type MMTV mice and a triple transgenic mouse SPC-rtTA(+/-)TetoCre(+/-)LoxP-VEGF-A(+/

267 ma by transfer of Th2 cells from a novel TCR transgenic mouse, specific for the major B. tropicalis a

268 BZ protein alone in vivo, we generated a new transgenic mouse strain that expresses HBZ mRNA altered

269 We use a transgenic mouse strain that ubiquitously expresses a mo

270 Here, we developed transgenic mouse strains that allow for tamoxifen-induci

271 Transgenic mouse studies confirmed that donor islet-spec

272 Transgenic mouse studies establish PRKCI as an ovarian c

273 (CLL) is the most common human leukemia, and transgenic mouse studies indicate that activation of the

274 In 1991, a set of transgenic mouse studies took the fields of cell biology

275 the aggressive form of this disease based on transgenic mouse studies.

276 this study, we analyzed these processes in a transgenic mouse system in which TCR-transgenic Th cells

277 To this end, we used a transgenic mouse system that allows diphtheria toxin-bas

278 We developed a transgenic mouse system that provides spatiotemporal inh

279 Here we provide evidence in a transgenic mouse system using ovalbumin (OVA) as a model

280 Using transgenic mouse technology, we show that Shp2 is involv

281 The HIV-1 transgenic mouse Tg26 carries a noninfectious HIV-1 prov

282 We generated a transgenic mouse that has one copy of the human TBK1 gen

283 We recently developed the Deltap35KI transgenic mouse that is deficient in p25 generation and

284 nvolved in isotype switching, we generated a transgenic mouse that over-expressed RNase H1, an enzyme

285 Here we use a transgenic mouse to interrogate both the characteristic

286 g, imaging and mass spectrometry, we use our transgenic mouse to label and analyze proteins in excita

287 eaky tetracycline promoter system in the Tat-transgenic mouse to show that a chronic very low-level e

288 4.5 (E14.5) Yap conditional knockout and YAP transgenic mouse tooth germs using transcriptome sequenc

289 d, TGFbeta2 was high in four MMTV-Hoxb7/Her2 transgenic mouse tumor cell lines and two breast cancer

290 we generated a doxycycline suppressible Cre transgenic mouse under the regulation of the Nkx2.5 enha

291 Furthermore, expressing FGFR3b-S243C in transgenic mouse urothelium expressing SV40T converted c

292 Using a Kaede transgenic mouse, we demonstrated enhanced leukocyte tra

293 earing, or retrograde tracing in a MET(EGFP) transgenic mouse, we identify three novel subpopulations

294 a causative role in OA, we used the p16-3MR transgenic mouse, which harbors a p16(INK4a) (Cdkn2a) pr

295 te these results in vivo by generating a BAC transgenic mouse, which overexpresses Cyfip1 under the e

296 This hCD22 transgenic mouse will be a valuable model for investigat

297 We crossed a Wnt1-Cre transgenic mouse with a double-tandem Tomato reporter st

298 address this, we have developed "mito-QC," a transgenic mouse with a pH-sensitive fluorescent mitocho

299 ted gene-1(AEG-1)/metadherin in NASH using a transgenic mouse with hepatocyte-specific overexpression

300 and secondary hepatic damage, we generated a transgenic mouse with liver-selective expression of NPC1